Back to Search
Start Over
Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
- Source :
- Cells, Vol 8, Iss 1, p 12 (2018), Cells
- Publication Year :
- 2018
- Publisher :
- MDPI AG, 2018.
-
Abstract
- Ocrelizumab, a humanized monoclonal anti-CD20 antibody, has shown pronounced effects in reduction of disease activity in multiple sclerosis (MS) patients and has recently been approved for the treatment of patients with relapsing MS (RMS) and primary progressive MS (PPMS). CD20 is mainly expressed by B cells, but a subset of T cells (CD3+CD20+ T cells) also expresses CD20, and these CD20+ T cells are known to be a highly activated cell population. The blood of MS patients was analyzed with multicolor flow cytometry before and two weeks after treatment with ocrelizumab regarding the phenotype of peripheral blood mononuclear cells. CD20-expressing CD3+ T cells were found in blood samples of all MS patients, accounted for 2.4% of CD45+ lymphocytes, and constituted a significant proportion (18.4%) of all CD20+ cells. CD3+CD20+ T cells and CD19+CD20+ B cells were effectively depleted two weeks after a single administration of 300 mg ocrelizumab. Our results demonstrate that treatment with ocrelizumab does not exclusively target B cells, but also CD20+ T cells, which account for a substantial amount of CD20-expressing cells. Thus, we speculate that the efficacy of ocrelizumab might also be mediated by the depletion of CD20-expressing T cells.
- Subjects :
- Adult
Cytotoxicity, Immunologic
Male
0301 basic medicine
CD3
T cells
Antibodies, Monoclonal, Humanized
multiple sclerosis
Peripheral blood mononuclear cell
CD19
CD3+CD20+
03 medical and health sciences
Multiple Sclerosis, Relapsing-Remitting
0302 clinical medicine
Antigen
Recurrence
T-Lymphocyte Subsets
immune system diseases
hemic and lymphatic diseases
medicine
Humans
Immunologic Factors
PPMS
CD20
Ocrelizumab
lcsh:QH301-705.5
Aged
B-Lymphocytes
B cells
biology
Chemistry
Brief Report
General Medicine
Middle Aged
Multiple Sclerosis, Chronic Progressive
RMS
Antigens, CD20
Molecular biology
030104 developmental biology
lcsh:Biology (General)
Monoclonal
Disease Progression
biology.protein
Female
Antibody
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- ISSN :
- 20734409
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Cells
- Accession number :
- edsair.doi.dedup.....37221995335d9559819adbed77e172a0
- Full Text :
- https://doi.org/10.3390/cells8010012